TRDA Entrada Therapeutics, Inc.
P/E
--
Forward P/E
3333.33
Price/Sales
36.64
Beta
-0.238
Div Yield
--
Market Cap
--
Company Analysis
Latest News
Entrada Therapeutics reported a narrower third quarter 2026 loss as cash runway extended into late 2027
Entrada Therapeutics reported third quarter 2026 results characterized by a narrower-than-anticipated net loss and a strategic extension of its liquidity...
Entrada Therapeutics Inc Q3 2026 Earnings Preview: What Analysts Expect on November 05, 2026
Entrada Therapeutics is expected to report Q3 2026 results on November 5, with analysts forecasting a consensus revenue of $2.13 million and an EPS loss of...